Shulamit Ron-Bigger
CIK: 0002049407
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)3 (75.0%)
Position reduction
Option Exercises (M)1 (25.0%)
Derivative conversions
Awards (A)0 (0.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
AKTS
Aktis Oncology, Inc.
Officer
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jul 8, 2026AKTS
Aktis Oncology, Inc.
Exercise(M)Direct50K shares at avg. $3.66$183K - Jul 8, 2026AKTS
Aktis Oncology, Inc.
Sale(S)Direct15.8K shares at avg. $27.13$429K - Jul 8, 2026AKTS
Aktis Oncology, Inc.
Sale(S)Direct30K shares at avg. $27.94$838K - Jul 8, 2026AKTS
Aktis Oncology, Inc.
Sale(S)Direct4.2K shares at avg. $28.75$121K
1-4 of 4 transactions
About Ron-Bigger Shulamit
Ron-Bigger Shulamit (SEC CIK 0002049407) files insider reports with the SEC as Chief Operating Officer of Aktis Oncology, Inc. (AKTS).
Signal8 holds 2 ownership filings by Ron-Bigger Shulamit (1 Form 3, 1 Form 4), filed between Jan 8, 2026 and Jul 10, 2026. Those filings report 4 transactions, the latest on Jul 8, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Ron-Bigger Shulamit's filings is in BOSTON, MA.
Recent filings by Ron-Bigger Shulamit
Other insiders filing for Aktis Oncology, Inc. (AKTS)
- Czibere Akos, Chief Medical Officer
- Herrmann Ken, Director
- Gormley Glenn, Director
- ELI LILLY & Co, 10% Owner
- Foley Todd, Director
- MPM BIOVENTURES 2018, L.P., 10% Owner